Summit Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert W. Duggan
- Full Time Employees
- 265
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 Brickell Key Drive Miami FL United States of America 33131
- IPO Date
- Mar 5, 2015
- CIK
- 0001599298
- Website
- smmttx.com
- Similar Companies
- Business
- Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies. The company develops ivonescimab, a novel bispecific antibody combining PD-1 blockade for immunotherapy with anti-VEGF-mediated anti-angiogenesis effects; ivonescimab is in global Phase III clinical trials, including HARMONi and HARMONi-3 for EGFR-mutated non-small cell lung cancer (NSCLC), HARMONi-6 for squamous NSCLC, HARMONi-7, and the recently announced HARMONi-GI3 for first-line metastatic colorectal cancer, with over 2,800 patients treated to date across trials. Summit holds exclusive licenses for ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, while partner Akeso, Inc. retains rights in other regions and conducts trials in China and Australia. Founded in 2003 and headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, the company targets solid tumors such as NSCLC and colorectal cancer. Recent developments include a $500 million private placement in October 2025 to fund operations and U.S. trial site openings for HARMONi-GI3 by year-end; collaborations with Pfizer to combine ivonescimab with antibody-drug conjugates and with Revolution Medicines for RAS(ON) inhibitors in NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer; positive HARMONi-6 top-line results in 2025 showing a 40% reduction in progression or death risk in squamous NSCLC; and completion of HARMONi enrollment with favorable survival trends in Western patients.
Company News
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of “Hold” from Analysts
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches